Ophthalmologic Manifestations of Cicatricial Pemphigoid Treatment & Management

  • Author: C Stephen Foster, MD, FACS, FACR, FAAO; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Aug 23, 2011
 

Medical Care

No topical agent is effective in stopping OCP activity. In selected patients, subconjunctival steroid injections or subconjunctival injections of mitomycin C may be used temporarily for slowing disease progression, while systemic therapy takes effect.

Adjuvant treatment with topical lubricants should be used in patients with dry eye symptoms. The use of topical cyclosporine and tacrolimus ointment has also been described in anecdotal reports to aid in the control of surface inflammation.[6]

  • Systemic corticosteroids can control the activity of the disease; however, they are not as effective as other immunosuppressive drugs, and the doses required have been shown to be very toxic. Additionally, tapering of systemic steroids has always been associated with recurrence of disease activity, suggesting the need of high doses for extended periods of time. Because of the toxicity of long-term corticosteroid use (eg, aseptic hip necrosis, pathological fractures, uncontrolled diabetes mellitus, hypertension), it is an unacceptable treatment. Corticosteroids should never be used as a sole agent. Their use should be reserved only for severely inflamed eyes that do not readily respond to immunosuppression alone. When administered, corticosteroids should be used for a limited period of time, preferably not longer than 3 months.[7]
  • Long-term use (>1 y) of systemic immunomodulators is the major therapeutic strategy in treating OCP. The current guidelines for using chemotherapy in treating OCP are as follows:
    • For mild-to-moderate inflammation, diaminodiphenylsulfone (Dapsone) is a first-line agent, provided the patient is not glucose-6-phosphate dehydrogenase deficient. Methotrexate may also be considered first-line therapy. If therapeutic response is not satisfactory, or if the use of Dapsone is contraindicated, or if the patient cannot tolerate the drug, mycophenolate mofetil or azathioprine can be substituted. If inflammation persists, cyclophosphamide can be used sequentially.
    • For severe inflammation, cyclophosphamide should be used initially, and systemic prednisone could be added with rapid taper for a limited period of time (3 mo).
    • Patients with active conjunctival inflammation refractory to chemotherapy or patients who do not tolerate the spectrum of immunosuppressive drugs can be treated with intravenous immunoglobulin (IVIg) or a combination of IVIg and rituximab infusions.[8, 9] Combination IVIg plus rituximab therapy may be the treatment approach with the highest likelihood of induction of durable remission and drug-free cure[10] ; the cost of such therapy may actually be less than the other therapeutic approaches, although such cost may appear to be the highest.[11] Additionally, since such therapy is not FDA-approved for labeling for treating OCP, obtaining insurance carrier coverage for such off-label use may require considerable effort.
Next

Surgical Care

Ocular surgical procedures should only be performed when the inflammation is completely under control, and systemic corticosteroids should be used perioperatively, when the procedure involves the conjunctiva or the cornea. Once the inflammation is suppressed, such procedures as marginal rotation of the eyelid, mucous membrane grafting, retractor plication, fornix reconstruction, or cataract extraction can be performed without significant danger of excessive postoperative inflammation and cicatrization.

  • Epilation
    • Aberrant lash growth that produces damage to the ocular surface is common in OCP. Extraction of these lashes and destruction of the follicles is important not only to prevent further irritation of the ocular surface but also to remove a factor that can mimic immunologically driven conjunctival inflammation, thereby hindering judgment regarding clinical response to chemotherapy and disease activity.
    • Mechanical epilation has only a temporary effect, and the lashes that regrow may be more deleterious than the original lashes. Gas permeable scleral contact lenses can be used to provide protection to the ocular surface from injury by aberrant lashes.
    • In case of trichiasis or distichiasis, permanent destruction of the lash follicles is ideal, although not easy to provide. Cryodestruction of lash follicles requires subsequent epilation in 10% of patients. The recurrences can be retreated.
  • Punctual occlusion
    • Treat dry eye syndrome with punctal occlusion and ocular lubricants without preservatives. Ocular hydration also can be increased with the use of twice daily mild steroid and topical cyclosporine.
    • Treat meibomian gland dysfunction with warm compresses and lid massages with eyelid hygiene, with or without systemic tetracycline therapy.
  • Lid surgery
    • Entropion surgery usually is avoided in patients with OCP because of the interference with the conjunctiva. Recently, several cases of lower lid entropion have been treated successfully with a retractor plication technique. The procedure is repeatable in case of undercorrection. Moreover, the conjunctiva remains intact during the surgery, which can avoid the exacerbation of conjunctival inflammation.
    • Tarsorrhaphy can be used in case of lagophthalmos, corneal hypoesthesia, or corneal epithelial defects.
  • Fornix reconstruction
    • Amniotic membrane transplantation or autologous oral mucosa can be used to reconstruct the conjunctival fornices in patients with OCP.
    • Mucous membrane grafting should not be performed when patients have severe keratoconjunctivitis sicca, advanced OCP, or active conjunctival inflammation. The procedure not only reconstructs the anatomy of fornices but also provides nonkeratinizing epithelium with goblet cells supplying mucous production to the ocular surface.
    • The beneficial long-term effect of this procedure is provided in approximately one third of the patients.[12]
  • Corneal surgery
    • The visual acuity in patients with OCP is impaired mostly by corneal pathology. Unfortunately, the spectrum of procedures on the cornea providing a satisfactory long-term visual outcome is very limited. Corneal transplantation on a dry eye with impaired lid function and limbal stem cell deficiency has a very poor prognosis; therefore, corneal grafting in patients with advanced OCP should be avoided. This procedure should only be performed in case of corneal perforation.
    • In patients with advanced corneal damage from OCP, keratoprosthesis may be the only feasible alternative for visual rehabilitation. Necrosis of the tissue surrounding the prosthesis is the major problem limiting the long-term outcomes. This process can lead to aqueous leak, retinal detachment, infection, and extrusion of the prosthesis. Recent advances in keratoprosthesis along with lifelong use of topical antibiotics have improved the outcome. At one facility, 5-8 patients had considerable improvement of visual acuity over a 5-year period.
  • Cataract surgery
    • The need for cataract surgery is common in patients with OCP. Cataract surgery performed on patients with OCP is followed by increased conjunctival inflammation, rapid progression of keratopathy, and conjunctival scarring, if the disease is not medically controlled.
    • The results of one study showed that a worse outcome of cataract surgery was associated with chemotherapy intolerance or the presence of any preoperative conjunctival inflammation. Similar to other surgical procedures for OCP, the use of perioperative systemic steroids is necessary in patients who are on systemic immunosuppressive therapy and in those patients whose inflammation is currently in remission without taking any immunosuppressive agents.[13]
Previous
Next

Consultations

  • Consult an appropriate specialist in case of skin involvement or involvement of other mucous membranes. Patients who have difficulty swallowing or breathing require an immediate endoscopic examination looking for esophageal webs, as these patients are at risk of asphyxiation.
  • Patients receiving chemotherapy may require regular consultations with a chemotherapeutist.
  • Patients should be referred to an ear, nose, and throat specialist for laryngoscopy in case of recent onset of hoarseness, which may be caused by laryngeal stenosis and tracheal scarring. These patients are in a medical emergency because of the risk of mucous accumulation and subsequent fatal asphyxiation. A statim laryngoscopy is essential, and it may be a life-saving procedure.
Previous
Next

Activity

Patients may be limited by visual acuity.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

C Stephen Foster, MD, FACS, FACR, FAAO  Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution

C Stephen Foster, MD, FACS, FACR, FAAO is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Association of Immunologists, American College of Rheumatology, American College of Surgeons, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, American Uveitis Society, Association for Research in Vision and Ophthalmology, Massachusetts Medical Society, Royal Society of Medicine, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Rola Hamam, MD  Assistant Professor, Department of Ophthalmology, American University of Beirut

Rola Hamam, MD is a member of the following medical societies: American Academy of Ophthalmology and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Erik Letko  MD, Corneal Consultants of Colorado

Disclosure: Nothing to disclose.

Specialty Editor Board

Jerre Freeman, MD  Founder and Chairman, Memphis Eye and Cataract Associates; Clinical Professor, Department of Ophthalmology, University of Tennessee Health Science Center College of Medicine

Jerre Freeman, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, and Tennessee Medical Association

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD  Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD  Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Institute

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery, and Pan-American Association of Ophthalmology

Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other; Vistakon Honoraria Speaking and teaching; EyeGate Pharma Consulting; Inspire Consulting fee Consulting; Bausch & Lomb Honoraria Speaking and teaching; Bausch & Lomb Consulting fee Consulting

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References
  1. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527-663. [Medline].

  2. Chan RY, Bhol K, Tesavibul N, et al. The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. Sep 1999;40(10):2283-90. [Medline].

  3. Nguyen QD, Foster CS. Cicatricial pemphigoid: diagnosis and treatment. Int Ophthalmol Clin. Winter 1996;36(1):41-60. [Medline].

  4. Cordero Coma M, Yilmaz T, Foster CS. Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid. Acta Ophthalmol Scand. Nov 2007;85(7):753-5. [Medline].

  5. Power WJ, Neves RA, Rodriguez A, et al. Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid. Ophthalmology. Aug 1995;102(8):1158-63. [Medline].

  6. Hall VC, Liesegang TJ, Kostick DA, et al. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol. Aug 2003;139(8):1083-4. [Medline].

  7. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. Apr 1982;89(4):340-53. [Medline].

  8. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology. Nov 1999;106(11):2136-43. [Medline].

  9. Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology. Jul 2004;111(7):1380-2. [Medline].

  10. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. May 2010;117(5):861-9. [Medline].

  11. Daoud Y, Amin KG, Mohan K, Ahmed AR. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study. Ann Pharmacother. Dec 2005;39(12):2003-8. [Medline].

  12. Heiligenhaus A, Shore JW, Rubin PA, et al. Long-term results of mucous membrane grafting in ocular cicatricial pemphigoid. Implications for patient selection and surgical considerations. Ophthalmology. Sep 1993;100(9):1283-8. [Medline].

  13. Sainz de la Maza M, Tauber J, Foster CS. Cataract surgery in ocular cicatricial pemphigoid. Ophthalmology. Apr 1988;95(4):481-6. [Medline].

  14. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. Jun 1991;98(6):858-62. [Medline].

  15. Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol. 1992;82(3):223-9. [Medline].

  16. Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. Feb 2008;115(2):253-261.e1. [Medline].

Previous
Next
 
Ocular cicatricial pemphigoid, stage II. Note the fornix foreshortening.
Ocular cicatricial pemphigoid, stage III. Note the symblepharon.
Ocular cicatricial pemphigoid, stage IV. Note the ankyloblepharon and ocular surface keratinization.
Corneal neovascularization with ulceration and stromal thinning after persistent epithelial defect in a patient with ocular cicatricial pemphigoid.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.